FDA Extends Comment Period for Draft Guidance on Synthetic Peptide Drug Products

Summary

The FDA is extending the comment period for its draft guidance on Abbreviated New Drug Applications (ANDAs) for certain highly purified synthetic peptide drug products that refer to listed drugs of recombinant deoxyribonucleic acid origin, following public interest and requests for additional time to submit comments.